Track Bullfrog AI Holdings Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Bullfrog AI Holdings Inc. Common Stock BFRG · Stock Open Bullfrog AI Holdings Inc. Common Stock in new tab

0.5415 USD
EPS
-0.46
P/B
1.44
ROE
-130.71
Beta
-2.62
Loading chart...
Key Metrics
Earnings dateMarch 18, 2027
EPS-0.46
Book Value0.38
Price to Book1.44
Debt/Equity1.29
% Insiders13.542%
Growth
Revenue Growth5.48%
Estimates
Forward P/E-3.19
Forward EPS-0.17

DCF valuation

Model fair value for Bullfrog AI Holdings Inc. Common Stock (BFRG)
Result
Sign in to run the valuation for BFRG.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Bullfrog AI Holdings Inc. Common Stock Logo Bullfrog AI Holdings Inc. Common Stock Analysis (BFRG)

United States Information Technology Official Website Stock

Is Bullfrog AI Holdings Inc. Common Stock a good investment? Bullfrog AI Holdings Inc. Common Stock (BFRG) is currently trading at 0.5415 USD.

Earnings Schedule: Bullfrog AI Holdings Inc. Common Stock is expected to release its next earnings report on March 18, 2027. The market consensus estimate for Forward EPS is -0.17.

Investor FAQ

Does Bullfrog AI Holdings Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Bullfrog AI Holdings Inc. Common Stock?

Bullfrog AI Holdings Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 18, 2027. The company currently has a trailing EPS of -0.46.

Company Profile

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole, which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Exchange Ticker
NMS (United States) BFRG
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion